Clinical trials
Relapsed or Refractory Hematologic Malignancies clinical trials
Below are recruiting relapsed or refractory hematologic malignancies clinical trials, each written for real people, not researchers. We’re tracking 1,350 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06785415RecruitingPhase 1/Phase 2
Study of a drug combo for relapsed multiple myeloma
This trial tests a combination of two antibody drugs (elotuzumab and daratumumab) plus an oral pill (iberdomide) and a steroid (dexamethasone) for people whose multiple myeloma has come back after treatment. The goal is to see if this new mix works better than what's already available.
Rochester, MinnesotaAges 18 years+ - NCT06789848RecruitingPhase 2
Testing two immunotherapy drugs for advanced liver and bile duct cancers
This trial tests two investigational drugs, ligufalimab and cadonilimab, for people with advanced liver cancer (hepatocellular carcinoma, HCC) or bile duct cancer (biliary tract cancer, BTC) that has not responded to previous treatment with an immunotherapy drug. The goal is to see if this combination can shrink tumors or slow cancer growth.
Dallas, TexasAges 18 years+ - NCT06796517Recruiting
Immunotherapy for relapsed or refractory lymphoma
This trial tests immunotherapy for people with certain types of lymphoma (diffuse large B cell, primary mediastinal, high grade, or Burkitt) that came back or didn't respond to previous treatment. It aims to see if a new immune-based approach can help.
SeoulAges 19–74 - NCT06799611RecruitingPhase 2
CM336 for immune thrombocytopenia (ITP)
This trial tests a new drug called CM336 for people with immune thrombocytopenia (ITP) that hasn't responded well to other treatments. It aims to see if CM336 can safely help raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06819670RecruitingPhase 2
Preventing infantile spasms from coming back
This trial tests whether a longer course of steroids can keep infantile spasms from returning in babies who have already responded to standard treatment. It may help reduce the chance of relapse.
Los Angeles, CaliforniaAges 2 months–1.5 years - NCT06822829Recruiting
Study of lymphoma that returned as slow-growing type
This study looks at people whose diffuse large B-cell lymphoma came back as a slower-growing lymphoma. Doctors want to understand how and why this happens, using medical records from diagnosis through follow-up.
Reggio EmiliaAges 18 years+ - NCT06826118RecruitingPhase 2
Car t-cell therapy for relapsed follicular lymphoma
This trial tests a new car t-cell treatment (axicabtagene ciloleucel) for people with follicular lymphoma that has come back or not responded after at least two prior treatments. It aims to see if this therapy can help control the lymphoma.
Xiamen, FujianAges 18 years+ - NCT06828042RecruitingPhase 1/Phase 2
CAR-γδT cells for refractory autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
BeijingAges 18–80 - NCT06838962RecruitingPhase 2
Study of anti-CD38 antibody for children with chronic ITP
This trial tests a new antibody treatment (anti-CD38) for children ages 6 to 18 who have had low platelets for at least 3 months and did not improve with steroids. The goal is to see if this treatment can safely raise platelet counts.
Tianjin, Tianjin MunicipalityAges 6–18 - NCT06839105RecruitingPhase 1
Testing AWT020 for advanced cancers
This study tests an experimental drug called AWT020 in people with advanced cancers that have either stopped responding to standard treatments or aren't candidates for them. The goal is to see if AWT020 is safe and tolerable across several cancer types such as lung cancer, melanoma, colorectal cancer, kidney cancer, and others.
Fuzhou, FujianAges 18 years+ - NCT06845592Recruiting
Stronger radiation and cell therapy before stem cell transplant for high-risk leukemia
This trial tests a special transplant approach for people with high-risk acute leukemia. It uses a stronger dose of radiation before transplant, followed by an infusion of immune cells (regulatory and conventional T cells) to help the transplant work better and fight the leukemia.
Perugia, PGAges 18–65 - NCT06846905Recruiting
Cost and effects of raising the dose of myeloma drugs at home vs. hospital
This study compares whether raising the dose of your current bispecific antibody is more cost-effective when done as an outpatient (day hospital) or as an inpatient. It aims to find the best way to manage your treatment safely.
ToulouseAges 18 years+ - NCT06847269RecruitingPhase 2
CAR T cell therapy for children and young adults with CD19+ leukemia
This trial tests an immunotherapy called CAR T cells for leukemia that has come back or is hard to treat. It aims to use your own immune cells to fight the cancer.
Memphis, TennesseeAges Up to 21 years - NCT06849986RecruitingPhase 2
Immunotherapy & AI for first-line soft tissue sarcoma
This trial tests a combination of immunotherapy (a treatment that helps your immune system attack cancer) and artificial intelligence (AI) technology as the first treatment for certain types of advanced soft tissue sarcoma. It aims to see if this approach can shrink tumors or stop them from growing better than current options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06851988Recruiting
Can exercise boost immunity and reduce head and neck cancer relapse?
This study tests whether a supervised exercise program can boost your immune system and lower the chances of cancer coming back after chemoradiation for head and neck cancer.
New Taipei CityAges 20–80 - NCT06863259RecruitingPhase 1
Study of a drug combo for relapsed B-cell leukemia
This trial tests a combination of three drugs (Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone) for children and young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back after treatment. It may help those whose leukemia has not responded to standard therapy or who have relapsed after a stem cell transplant or CAR-T therapy.
Cincinnati, OhioAges 1–39 - NCT06863974Recruiting
Finding markers of relapsing nerve inflammation in children
This study looks at children who have had a first attack of nerve inflammation (like ADEM, vision loss, or spinal cord issues) to find markers in the blood that might show if it will come back. It tests blood and cells to better understand the immune response.
AngersAges 18 years+ - NCT06864936Recruiting
Eye scan study for ublituximab in multiple sclerosis
This study uses a special eye scan (OCT) to see how well the MS medication ublituximab works. It compares people starting ublituximab to those on other stable MS treatments, to find better ways to measure treatment success.
Baltimore, MarylandAges 18–65 - NCT06865664RecruitingPhase 1
Engineered immune cells for relapsed rhabdomyosarcoma in youth
This early-phase trial tests a new immune cell therapy (CAR T cells) for children and young adults whose rhabdomyosarcoma has returned or not responded to standard treatments. The goal is to see if these specially engineered cells can find and attack the cancer.
Bethesda, MarylandAges 3–39 - NCT06880393RecruitingPhase 2
BCMA CAR-T for high-risk multiple myeloma
This trial tests a new immunotherapy called BCMA CAR-T for people with multiple myeloma that is considered high-risk. It aims to see if this treatment can help patients who had a short response to initial therapy or have specific genetic changes in their cancer.
TianjinAges 18–75 - NCT06888921RecruitingPhase 1/Phase 2
COM701 for platinum-sensitive ovarian cancer
This study tests a new drug, COM701, for people with ovarian cancer that came back after treatment but still responds to platinum-based chemotherapy. It aims to see if COM701 is safe and effective for patients who have already tried several treatments.
Augusta, GeorgiaAges 18 years+ - NCT06894602Recruiting
Can Ultrasound Predict Relapse in Giant Cell Arteritis?
This study uses an ultrasound of the temporal artery (a vessel in your temple) to see if certain findings can predict whether giant cell arteritis will come back. It may help doctors know who needs closer monitoring.
BrestAges 18 years+ - NCT06904196RecruitingPhase 2
Lenvatinib with or without internal radiation for TACE-resistant liver cancer
This trial compares two treatments for liver cancer (HCC) that has stopped responding to TACE. One group gets lenvatinib (a targeted therapy pill) plus SIRT (internal radiation beads placed in the liver), and the other gets lenvatinib alone. The goal is to see which combination works better.
Guangzhou, GuangdongAges 18–75 - NCT06910124RecruitingPhase 2
Testing linvoseltamab with lenalidomide for multiple myeloma
This trial tests adding a new drug, linvoseltamab, to the standard maintenance therapy lenalidomide for people with newly diagnosed multiple myeloma. The goal is to see if it can deepen responses or turn a relapse back to a negative minimal residual disease (MRD) state, where no cancer cells are detectable.
Miami, FloridaAges Any age
Hear when a new Relapsed or Refractory Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory hematologic malignancies?
- Yes. Clin2 currently lists 1,350 recruiting relapsed or refractory hematologic malignancies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory hematologic malignancies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory hematologic malignancies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory B-cell Malignancies
- Relapsed/Refractory Hematological Malignancies
- Relapsed/Refractory Multiple Myeloma
- Relapsed/Refractory Acute Myeloid Leukemia
- Relapsed or Refractory Multiple Myeloma
- Relapsed or Refractory Multiple Myeloma (RRMM)
- Relapsed/Refractory B-cell Lymphoma
- Non-Hodgkin Lymphoma Refractory/ Relapsed
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.